|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
|
||
(Address of Principal Executive Offices) (Zip Code)
|
||
(
|
||
(Registrant’s telephone number, including area code)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered |
|
|
|
(a) |
The Annual Meeting of Shareholders of AngioDynamics was held on November 3, 2022. |
(b) |
Shareholders of AngioDynamics voted on the matters set forth below. |
|
1.
|
The nominees for election to the Board of Directors of AngioDynamics were elected, each as a Class I director to serve until the 2025 Annual Meeting of Shareholders of AngioDynamics and until their respective successors are duly elected and qualified, based upon the following votes: |
Nominee
|
Votes For
|
Withheld
|
Broker Non-Votes
|
||
Dennis Meteny
|
33,295,790
|
904,413
|
2,098,784
|
||
Michael Tarnoff
|
24,235,664
|
9,964,539
|
2,098,784
|
|
2.
|
The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics’ independent registered public accounting firm for the fiscal year ending May 31, 2023 was approved based upon the following votes: |
Votes for approval
|
36,261,992
|
||
Votes against
|
35,700
|
||
Abstentions
|
1,295
|
||
There were no broker non-votes for this item.
|
|
3.
|
The proposal to approve, on an advisory basis, AngioDynamics’ executive compensation of its named executive officers was approved based upon the following votes: |
Votes for approval
|
33,348,202
|
||
Votes against
|
848,967
|
||
Abstentions
|
3,034
|
||
Broker non-votes
|
2,098,784
|
|
4.
|
The proposal to approve the amended AngioDynamics, Inc. 2020 Equity Incentive Plan was approved based upon the following votes: |
Votes for approval
|
32,788,999
|
||
Votes against
|
1,410,624
|
||
Abstentions
|
580
|
||
Broker non-votes
|
2,098,784
|
|
5.
|
The proposal to approve the amended AngioDynamics, Inc. Employee Stock Purchase Plan was approved based upon the following votes: |
Votes for approval
|
34,054,111
|
||
Votes against
|
145,327
|
||
Abstentions
|
765
|
||
Broker non-votes
|
2,098,784
|
Exhibit No.
|
Description
|
AngioDynamics, Inc. 2020 Equity Incentive Plan, as amended (Incorporated by reference to Appendix A of the Registrant’s Definitive Proxy Statement
filed on September 22, 2022 in connection with the Annual Meeting held on November 3, 2022 (File No. 000-50761)).
|
|
AngioDynamics, Inc. Employee Stock Purchase Plan, as amended (Incorporated by reference to Appendix B of the Registrant’s Definitive Proxy Statement
filed on September 22, 2022 in connection with the Annual Meeting held on November 3, 2022 (File No. 000-50761)).
|
ANGIODYNAMICS, INC.
(Registrant)
|
|||
Date: November 4, 2022
|
By:
|
/s/ Richard C. Rosenzweig | |
Name: Richard C. Rosenzweig | |||
Title: Senior Vice President, General Counsel and Secretary | |||
Document and Entity Information |
Nov. 03, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Nov. 03, 2022 |
Entity File Number | 000-50761 |
Entity Registrant Name | ANGIODYNAMICS INC |
Entity Central Index Key | 0001275187 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 11-3146460 |
Entity Address, Address Line One | 14 Plaza Drive |
Entity Address, City or Town | Latham |
Entity Address, State or Province | NY |
Entity Address, Postal Zip Code | 12110 |
City Area Code | 518 |
Local Phone Number | 795-1400 |
Title of 12(b) Security | Common Stock, par value $0.01 per share |
Trading Symbol | ANGO |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G
%'\GD3L:\# E;LQI"AV,$C^\)1_CB++89[><7%Y=
M>'[ B:)T9*DC=W3)DDH=]*+A./9O^RD!R'72)CC&\O/M=@'H@*>4X(C;_-\C
M_^[#3B\*4WAW^P:0N4/<[->'G90_I%V! =*%9P^[.0K@JP/X)$DZ#OB''0_:
MMSU ;C#>)\>Q3X,6^<*#.Y[Z+FV1! 03)#CVO0,BFB;^GWR?R-(P/2#XBC8-
M_-MPGP3<@RMN%$3Q/OE%$G\'Q*'N]]L8!(2UBUN>^#M NAPR_X[X[,/.R?7E
M)Q\UP1>?,1[N%, Q/QD&% +HY##(X?^PSX.@\?95]%:?(4&YT""V'<)< H^
MROW]8Z )0[I\"NCMCGC3)^JF_V2.0PV':JK-' C0G2\?,/CQQ,_?CM>AQJL09T2
MOUM.58A!Y7=X.QJW >VWVC&)6QG4=&=0XF\/G1(?>]7D=\72S-V&-7/XVT/J1\O"XH9%!QL;G3
M\^./0)OE=DMRRHEH/]L'U)G$4+UZ23,-7-,<#!:D2_C!0Z9L^?Q#T/^(9L%^^'S.6'GS[-YDE(_2(53
M-HG3 1A+PY2/78F-Y8'R?&FH%"=D0P.L]*"-X',TCUZU2-(>YT,SF:XCUBV_
M,L#Q\-/] (4+DW:6-:%_1.._;\?[4>LS/:/ROO@T$$-B'RNF42C& 6$GRZ=T
M*,UH2